Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCBT with Non-Myeloablative Regimen in Hematological Diseases
NCT02722668Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2017
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Burkitt lymphoma (BL) and 20 more (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Probability of Acute Graft Versus Host Disease at Day 100. Started May 2017; status: completed.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)natural killer cell neoplasmchronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT02722668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722668.